

DEPARTMENT OF ALCOHOL AND DRUG PROGRAMS

1700 K STREET
 SACRAMENTO, CA 95814-4037
 TDD (916) 445-1942
 (916) 322-7012

**ADP BULLETIN**

| | | | |
|---|--|---|------------------------|
| Title BUPRENORPHINE | | Issue Date: 02-11-05 Expiration Date: Until Notified | Issue No. 05-01 |
| Deputy Director Approval (signed by) Rebecca Lira Licensing and Certification Division | Function: [] Information Management [] Quality Assurance [X] Service Delivery [] Fiscal [] Administration | Supersedes Bulletin/ADP Letter No. | |

PURPOSE

The purpose of this bulletin is to request Narcotic Treatment Program (NTP) providers for additional information when reporting Buprenorphine on the California Alcohol and Drug Data System (CADDs) form for each admission. This bulletin supersedes the December 30, 2004, letter regarding this issue.

DISCUSSION

As requested in the December 30, 2004, letter, the Department of Alcohol and Drug Programs (ADP) is requesting NTP providers to identify "Other" under "Medication Prescribed" on the CADDs form and to also include a "Y" for yes or "N" for no in box number 11 of the "Coded Remarks" section. This additional information will further clarify the medication being used is Buprenorphine. Please do not leave these spaces blank.

REFERENCES

On December 30, 2004, a letter was sent to NTP providers announcing the establishment of Chapter 862, Statutes of 2004, Section 11839.2 of the Health and Safety Code. This amendment added Buprenorphine as an approved medication for the use of narcotic replacement therapy, effective January 1, 2005.

BACKGROUND

In October 2000 the Food and Drug Administration (FDA) approved Buprenorphine as a medication for opiate dependency for NTP's and private physicians. Due to the restriction in California's Statute to allow only Methadone and LAAM for narcotic



DO YOUR PART TO HELP CALIFORNIA SAVE ENERGY
 For energy saving tips, visit the Flex Your Power website at
<http://www.flexyourpower.ca.gov>

replacement therapy, the California Health and Safety Code was amended to allow NTP physicians to use Buprenorphine. ADP is not regulating Buprenorphine; however, ADP will review program records pursuant to the federal regulations. In addition, physicians must be certified by the Substance Abuse and Mental Health Services Administration and comply with all federal requirements.

QUESTIONS/MAINTENANCE

If you have questions or require additional information, please contact Joan Robbins, Administrative Supervisor, Narcotic Treatment Program Licensing Branch at (916) 324-3084. .

DISTRIBUTION

County Alcohol and Drug Program Administrators
Strategic Local Government Services, LLC
Director's Advisory Council
Narcotic Treatment Program Providers
Narcotic Treatment Program Executives